Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy

Elissa Yozawitz, Arthur Stacey, Ronit M. Pressler

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Seizures are common in neonates with moderate and severe hypoxic ischemic encephalopathy (HIE) and are associated with worse outcomes, independent of HIE severity. In contrast to adults and older children, no new drugs have been licensed for treatment of neonatal seizures over the last 50 years, because of a lack of controlled clinical trials. Hence, many antiseizure medications licensed in older children and adults are used off-label for neonatal seizure, which is associated with potential risks of adverse effects during a period when the brain is particularly vulnerable. Phenobarbital is worldwide the first-line drug and is considered standard of care, although there is a limited evidence base for its efficacy. Second-line agents include phenytoin, benzodiazepines, levetiracetam, and lidocaine. These drugs are discussed in more detail along with two emerging drugs (bumetanide and topiramate). More safety, pharmacokinetic, and efficacy data are needed from well-designed clinical trials to develop safe and effective antiseizure regimes for the treatment of neonatal seizures in HIE.

Original languageEnglish (US)
Pages (from-to)553-567
Number of pages15
JournalPediatric Drugs
Issue number6
StatePublished - Dec 1 2017

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy'. Together they form a unique fingerprint.

Cite this